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Oligometastatic lung cancer
A different lung cancer entity with 
different treatment approaches? 
Since the concept of oligometastatic state has been described in 1995,1 the interest in 
the heterogeneity of stage IV non-small cell lung cancer (NSCLC) has exponentially 
grown. To date, the correct definition of oligometastatic disease is still under debate as it 
describes a subset of patients with a more favorable disease compared to the 
counterpart with bulky diffusion of metastasis. In fact, up to 86 % 5-year survival rate has 
been reported2 for radical treatment of solitary metastasis while the general 5-year 
overall survival (OS) rate of stage IV NSCLC is less than 10 %.3
Definition of oligometastatic state 
A homogeneous definition of this state 
is mandatory when a radical treatment is 
technically feasible for all tumor sites and 
may modify the disease course leading to 
long-term survival.4 Recently a pan-Euro-
pean multidisciplinary consensus group 
established the criteria for synchronous 
oligometastatic disease definition, indica-
ting a maximum of 5 metastases in no 
 more than 3 organs.4 Positron emission 
tomography (PET-CT) has been considered 
mandatory for mediastinal staging (Fig. 1), 
even though not sufficient in all cases.
Treatment options
The mainstay of stage IV lung cancer 
remains the platinum-based palliative che-
motherapy, with additional therapeutic 
options being targeted therapies with al-
kaline phosphatase (ALK) or epidermal 
growth factor receptor (EGFR) inhibitors, 
and a number of immune-checkpoint inhi-
bitors. However, the recent improvements 
in surgery and radiotherapy have imposed 
the role of the local ablative treatments in 
the multi-modality approach for the oligo-
metastatic disease.
A provocative phase II trial conducted by 
Gomez et al. in 20165 was terminated early 
after the interim analysis showed signifi-
cantly better results in the interventional 
arm. The trial enrolled patients for local 
consolidative treatment (LCT) including 
chemo-radiotherapy (CRT), radiotherapy or 
resection vs. maintenance chemotherapy 
alone. At 12,4 months of follow-up the pro-
gression-free survival (PFS) was 11,9 for 
the interventional group and 3,9 months 
for the standard of care with an odds ratio 
(OR) of 0,35. A number of small prospec-
tive and retrospective studies also suggest 
that radical local therapies provide good 
results in long-term disease control.5–12
The role of surgery
As regards the best treatment for the 
primary site, large epidemiological databa-
ses analyses have been recently published. 
The first one,13 based on data extracted 
from the National Cancer Database, consi-
dered a population of over 3000 patients 
who underwent lung resection for stage IV 
NSCLC. It reported a 5-year OS of 21,1 %, 
recommending surgical resection for tu-
mors staged T1-2,N0-1,M1 or T3N0M1. In 
this series, information on metastasis 
 treatment was not provided, drawing only 
partial conclusions on definitive treatment. 
The second large population-based study 
was based on the Surveillance, Epidemio-
logy and End Results database.14 This re-
trospective analysis was conducted on over 
39 000 cases of stage IV NSCLC, of which 
1206 underwent surgical resection of pri-
mary tumor. The authors found that pri-
mary tumor resection was associated with 
significantly longer OS in different cohorts 
of patients. Other clinical studies favored 
surgery for the primary site as cornerstone 
treatment of oligometastatic NSCLC. As an 
example, the paper of Griffioen9 showed 
that, in a context of radical treatment, lung 
resections patients have better prognosis in 
terms of OS, PFS and survival after the first 
progression. These results were confirmed 
by Xu15, who reported that primary tumor 
excision conditioned the prognosis in pati-
ents with synchronous solitary metastasis.
The surgical resection of the metastatic 
sites has been reported to improve the out-
come. Congedo16, analyzing their long-
term results, found that the complete con-
trol of the metastatic lesion by surgery 
(more than with radiation or chemotherapy), 
had a beneficial impact on the disease- 
free survival (DFS). Overall, the paradigm 
of surgical strategy for metastasis treat-
ment started with the management of 
brain lesions and was extended to multiple 
organs with good results.17 Xu15 reported 
better results with the use of surgery or 
radiosurgery in the treatment of brain and 
adrenal metastasis, compared with those 
who did not receive it, while this diffe rence 
was not observed for bone lesions. They 
concluded that even in case of unusual me-
tastatic site aggressive treatments inclu-
ding surgery should be considered.
Although surgery seems to provide the 
best results, there is a potential selection 
bias favoring the outcomes. Surgical can-
didates have usually a good performance 
status, less medical comorbidities and lo-
wer burden of thoracic disease. Looking at 
the metastatic sites, many patients might 
present non-resectable deposits, as in most 
case of bone lesions, or being precluded 
from surgery for high surgical risk.
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A recent meta-analysis on the evolution 
of treatment strategies in oligometastatic 
NSCLC18 evidenced a considerable change 
in the management over the past 20 years. 
Initial treatment of choice for metastasis 
was surgery, while after 2011 (SBRT era), 
there has been an increased use of radio-
therapy, mostly in the form of SBRT and no 
difference in OS was observed between 
surgery and radiotherapy studies. These 
results may reflect the evolution in radio-
therapy strategies with the ability to deliver 
potentially ablative doses to different sites 
throughout the body, allowing curative 
 treatments for unresectable metastasis.19
Prognostic factors
Accurate patient’s selection remains cru-
cial for obtaining the best results when 
choosing a radical treatment. Different fac-
tors have been investigated for possible as-
sociation with prognosis, with the aim to 
select upfront the best candidates for ag-
gressive therapies. Sex, age, nodal status, 
performance status, intrathoracic stage, 
smoking status and histology have been the 
most advocated prognostic factors. In a 
 meta-analysis published by Shi and col-
leagues20, the nodal status was significant-
ly related with the OS. These results are in 
line with most published reports, either 
from clinical series or analysis of epidemio-
logical databases.15–18, 21–24 In this light, a 
complete nodal staging before radical treat-
ment is highly recommended.4, 20 Other 
studies reported that age and performance 
status influence the prognosis of these pati-
ents. Ampil25, in a series of 72 cases, found 
that patients with solitary metastasis youn-
ger than 65 years had a longer survival com-
pared to the older counterpart. It is intuitive 
that patients in better general conditions 
are more prone to be included in aggressive 
treatment programs. As an example, the 
study of Frost26 analyzed 107 patients who 
received local ablative treatments for syn-
chronous single organ metastatic lung can-
cer, comparing them with 266 patients who 
did receive palliative treatments. Good per-
formance status was strongly associated 
with better survival within the control 
group and remained associated with good 
outcome after propensity score matching of 
groups. The published literature generally 
indicates that patients in good clinical 
 conditions could be possibly selected for 
upfront aggressive treatments and for 
further therapies after first progression.
Future perspectives
Finally, a mention on the role of the 
multimodality approach is mandatory. 
Usually the literature supporting the use 
of systemic therapies involves patients 
with widespread metastatic tumors rather 
than with limited disease. However, a 
combined effect of immunotherapy and 
local ablative therapies has been observed 
in NSCLC, with benefits in disease cont-
rol.6, 10 The use of induction systemic the-
rapy may serve as selection criteria for 
patients who might experience long-term 
PFS with additional local ablative treat-
ments. In the era of immunotherapy, com-
bined treatments and the fascinating 
 “abscopal effect” with the combined use 
of immunotherapy and radiotherapy has 
been suggested.27
Take-home message
In conclusion, the oligometastic NSCLC 
represents a subset of stage IV lung cancer 
with a different biological behavior that 
may benefit from aggressive local treat-
ments in a context of multimodality ap-
proach. Current evidences push towards 
surgical resection of the primary tumor for 
selected patients along with surgical and/
or radiation therapy for all metastatic sites 
combined with systemic therapy. Herein 
the addition of immunotherapy seems to 
be very promising. More studies are 
 needed to better understand the tumor 
Fig. 1:  64-year-old patient with adenocarcinoma of the left upper lobe (white arrow) and left adrenal metastasis (white circle). A: PET scan at first diag-
nosis. B: Re-staging after induction therapy (3 cycles of chemo-immunotherapy with carboplatin, pemetrexed and pembrolizumab). C: No evidence of 
recurrent disease after one year from left upper lobectomy and left laparoscopic adrenalectomy
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biology, to tailor well-balanced treatments 
and to better select the patients.  ◼
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Krebsliga Schweiz würdigt Engagement
Dieses Jahr verleiht die Krebsliga Schweiz zwei Anerkennungspreise: einen an das mobile Palliative- 
Care-Team Voltigo in Freiburg und einen an die Schweizerische Gesellschaft für Psychoonkologie 
(SGPO). Ausserdem erhält Altbundesrätin Ruth Dreifuss die Krebsmedaille für ihr Engagement für 
bezahlbare Medikamente und die Zugangsgerechtigkeit in der medizinischen Versorgung.
M it dem mit 5000 Franken dotierten Anerkennungspreis zeichnet die 
Krebsliga Schweiz Personen und Organisa-
tionen aus, die die Situation von Krebsbe-
troffenen verbessern. Dieses Jahr verleiht 
die Krebsliga den Preis gleich zwei Mal: an 
das mobile Palliative-Care-Team Voltigo in 
Freiburg sowie an die SGPO.
Im Kanton Freiburg können an Krebs 
erkrankte Menschen und ihre Angehörigen 
seit zehn Jahren auf Voltigo zählen. Das 
mobile Palliative-Care-Team lindert die 
Leiden und pflegt die Kranken am Ort ih-
rer Wahl, auch bei ihnen zu Hause. Damit 
trägt es massgeblich zur bestmöglichen 
Lebensqualität der Betroffenen bei. Die 
SGPO wurde 2003 gegründet und hat die 
psychosoziale Begleitung und Betreuung 
von Krebsbetroffenen und ihren Angehöri-
gen institutionalisiert und professionali-
siert. Dadurch wurde ein wichtiger Beitrag 
zur Verbesserung von psychosozialen Un-
terstützungsdiensten geleistet.
Einsatz für mehr 
Zugangsgerechtigkeit
Mit der Krebsmedaille würdigt die 
Krebsliga Schweiz aussergewöhnliche Ver-
dienste im Kampf gegen Krebserkrankun-
gen und ihre Folgen. Die diesjährige Me-
daille geht an Altbundesrätin Ruth Drei-
fuss. Sie hat sich während – aber auch nach 
– ihrer Amtszeit sehr für bezahlbare Medi-
kamente und die Zugangsgerechtigkeit in 
der medizinischen Versorgung eingesetzt. 
(red) ◼
Quelle: 
Medienmitteilung Krebsliga Schweiz, 19. September 2019
